Browsing Tag
Precision Medicine
24 posts
I-SPY 2 data puts Natera’s Signatera at the center of early breast cancer risk debates
Natera’s I-SPY 2 data suggests ctDNA may finally align early breast cancer risk with treatment intensity. Read why this matters for payers and markets.
Johnson & Johnson grabs RIPTAC cancer tech in $3bn Halda Therapeutics deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding its oncology portfolio with precision prostate cancer treatments. Find out what’s next.
Can Swiss Rockets’ new CoolMPS deal with MGI Tech make Europe a genomics powerhouse?
Find out how Swiss Rockets AG’s exclusive license for MGI Tech’s CoolMPS sequencing platform could redefine genomics and precision medicine worldwide.
Pfizer data reveal sustained survival with BRAFTOVI + MEKTOVI in rare lung cancer subtype
Find out how Pfizer’s BRAFTOVI + MEKTOVI combination is redefining survival for BRAF V600E-mutant lung cancer and what it means for Pfizer’s oncology strategy.
Tempus joins forces with Whitehawk Therapeutics to power next-gen biomarker-based oncology trials
Find out how Tempus and Whitehawk are using AI and real-world data to transform biomarker-driven oncology—discover the collaboration’s science and market impact.
Inside the Monteris–Symphony alliance: Can AI-driven robotics make brain surgery safer and smarter?
Discover how Monteris Medical and Symphony Robotics are merging AI, robotics, and MRI precision to transform minimally invasive brain surgery.
Can this Golden Helix–Genomenon integration cut variant interpretation time in half?
Golden Helix integrates Genomenon's AI-powered genomic intelligence into VarSeq to streamline diagnostics. Explore how this boosts accuracy and speed in labs.
NeoGenomics appoints Merck oncology executive Dr. Marjorie Green to its board to advance leadership in precision diagnostics
NeoGenomics adds Merck oncology leader Dr. Marjorie Green to board, strengthening its precision diagnostics strategy and global pharmaceutical partnerships.
Valar Labs’ AI biomarkers validated in European Urology as superior risk predictors for bladder cancer
Valar Labs’ CHAI biomarkers validated in European Urology outperform standard methods in predicting outcomes for high grade Ta bladder cancer.
The future of biomedical research? Illumina’s spatial transcriptomics could unlock unprecedented discoveries
Illumina, Inc. has introduced an innovative spatial transcriptomics technology, designed to significantly enhance the mapping of complex tissues…